The Gut Microbiome and IBS: Exploring the Connection and Potential Therapeutic Approaches

Gut Microbiome and IBS

April is IBS Awareness Month, an annual campaign aimed at providing support and education for those living with Irritable Bowel Syndrome (IBS), as well as promoting research and advocacy efforts to find a cure for this condition. IBS is a common functional gastrointestinal disorder that affects up to 20% of the global population, causing abdominal pain, bloating, and altered bowel habits (Canavan et al., 2014).

Although the exact cause of IBS remains elusive, the gut microbiome has emerged as a key player in its pathophysiology (Simrén et al., 2013). This article explores the complex interplay between the gut microbiome and IBS and discusses potential therapeutic approaches targeting the gut microbiome, including probiotics, prebiotics, fecal microbiota transplantation (FMT), and diet modifications.

The Gut Microbiome and IBS

The gut microbiome, consisting of trillions of microorganisms, has been recognized as an essential factor in maintaining human health (Gopalakrishnan et al., 2018). It plays a vital role in nutrient metabolism, immune system development, and gut barrier function (Clemente et al., 2012). Dysbiosis, or an imbalance in the microbial community, has been linked to various gastrointestinal disorders, including IBS (Jeffery et al., 2012).

Dysbiosis in IBS

IBS patients exhibit alterations in microbial composition compared to healthy individuals, with reduced microbial diversity and an increased abundance of potentially harmful bacteria (Pittayanon et al., 2019). A meta-analysis by Pittayanon et al. (2019) reported a higher prevalence of Firmicutes and a lower prevalence of Bacteroidetes in IBS patients. Additionally, IBS patients show an increased ratio of Firmicutes to Bacteroidetes, which has been associated with low-grade inflammation and increased intestinal permeability (Jeffery et al., 2012).

Functional Alterations of the Gut Microbiome in IBS

IBS patients have a dysregulated production of short-chain fatty acids (SCFAs), primarily acetate, propionate, and butyrate, essential for gut health (Tana et al., 2010). SCFAs are the primary energy source for colonocytes, modulate the immune system, and maintain gut barrier function (Tana et al., 2010). Reduced butyrate production in IBS patients may contribute to visceral hypersensitivity and altered gut motility (Tana et al., 2010).

Altered bile acid metabolism is another functional alteration observed in IBS patients. Bile acids are critical for dietary fat absorption and modulate the gut microbiome composition (Camilleri, 2019). IBS patients exhibit an increased bile acid synthesis rate and reduced bacterial bile acid biotransformation, leading to increased colonic bile acid concentrations, which may contribute to diarrhea and abdominal pain (Camilleri, 2019).

Therapeutic Approaches Targeting the Gut Microbiome


Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit to the host (Hill et al., 2014). They can modulate the gut microbiome by promoting the growth of beneficial bacteria, inhibiting the growth of harmful bacteria, and enhancing the gut barrier function (Hill et al., 2014).

A meta-analysis by Ford et al. (2014) demonstrated that probiotics significantly reduced IBS symptoms, including abdominal pain, bloating, and flatulence. However, the efficacy of specific probiotic strains and the optimal dosage remain unclear, necessitating further research (Ford et al., 2014).


Prebiotics are non-digestible carbohydrates that selectively stimulate the growth and activity of beneficial gut bacteria, particularly Bifidobacteria and Lactobacilli (Gibson et al., 2017). Prebiotic supplementation has been proposed as a therapeutic approach for IBS due to its potential to restore microbial balance, enhance the production of SCFAs, and reduce inflammation (Gibson et al., 2017).

A systematic review by Wilson et al. (2017) found that prebiotic supplementation, particularly galactooligosaccharides, significantly improved global IBS symptoms and quality of life. However, larger and more robust clinical trials are needed to confirm these findings and identify the optimal prebiotic types and dosages for IBS patients.

Fecal Microbiota Transplantation (FMT)

FMT involves the transfer of fecal material from a healthy donor to an IBS patient, with the aim of restoring the recipient’s gut microbiota composition and functionality (Pamer, 2014). Preliminary studies have shown promising results for FMT in treating IBS, with improvements in gastrointestinal symptoms, gut microbiota composition, and quality of life (Halkjær et al., 2018).

However, the long-term safety and efficacy of FMT in IBS patients remain uncertain, and standardized protocols for donor selection, fecal material preparation, and administration routes need to be established (Halkjær et al., 2018).

Diet Modifications

Dietary interventions, such as the low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet, have been increasingly used in IBS management (Staudacher et al., 2017). The low FODMAP diet restricts the intake of fermentable carbohydrates, which can exacerbate IBS symptoms by increasing gas production and osmotic load in the gut (Staudacher et al., 2017).

A meta-analysis by Marsh et al. (2016) demonstrated that the low FODMAP diet significantly improved IBS symptoms, including abdominal pain, bloating, and diarrhea. However, the low FODMAP diet may also reduce the abundance of beneficial gut bacteria, warranting caution in its long-term use and emphasizing the importance of personalized dietary recommendations for IBS patients (Staudacher et al., 2017).

The gut microbiome plays a pivotal role in the pathophysiology of IBS, with dysbiosis and functional alterations contributing to the disorder’s clinical manifestations. Therapeutic approaches targeting the gut microbiome, including probiotics, prebiotics, FMT, and diet modifications, have shown promise in the management of IBS. Further research is needed to optimize these treatments, elucidate their mechanisms of action, and develop personalized therapeutic strategies for IBS patients.

Interested in topics like this? Join The Rounds Gastroenterology community for free and gain access to on-demand learning activities, medical peers, and curated clinical information.


Camilleri, M. (2019). Bile Acid diarrhea: prevalence, pathogenesis, and therapy. Gut and Liver, 9(3), 332-339.

Canavan, C., West, J., & Card, T. (2014). The epidemiology of irritable bowel syndrome. Clinical Epidemiology, 6, 71-80.

Clemente, J. C., Ursell, L. K., Parfrey, L. W., & Knight, R. (2012). The impact of the gut microbiota on human health: an integrative view. Cell, 148(6), 1258-1270.

Ford, A. C., Quigley, E. M., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., … & Moayyedi, A. (2014). Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. American Journal of Gastroenterology, 109(10), 1547-1561.

Gibson, G. R., Hutkins, R., Sanders, M. E., Prescott, S. L., Reimer, R. A., Salminen, S. J., … & Reid, G. (2017). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nature Reviews Gastroenterology & Hepatology, 14(8), 491-502.

Gopalakrishnan, V., Helmink, B. A., Spencer, C. N., Reuben, A., & Wargo, J. A. (2018). The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell, 33(4), 570-580.

Halkjær, S. I., Christensen, A. H., Lo, B. Z. S., Browne, P. D., Günther, S., Hansen, L. H., & Petersen, A. M. (2018). Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut, 67(12), 2107-2115.

Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., … & Calder, P. C. (2014). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology, 11(8), 506-514.

Jeffery, I. B., O’Toole, P. W., Öhman, L., Claesson, M. J., Deane, J., Quigley, E. M., & Simrén, M. (2012). An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut, 61(7), 997-1006.

Marsh, A., Eslick, E. M., & Eslick, G. D. (2016). Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. European Journal of Nutrition, 55(3), 897-906.

Pamer, E. G. (2014). Fecal microbiota transplantation: effectiveness, complexities, and lingering concerns. Mucosal Immunology, 7(2), 210-214.

Pittayanon, R., Lau, J. T., Yuan, Y., Leontiadis, G. I., Tse, F., Surette, M., & Moayyedi, P. (2019). Gut microbiota in patients with irritable bowel syndrome—A systematic review. Gastroenterology, 157(1), 97-108.

Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M., Spiller, R. C., Vanner, S., … & Zoetendal, E. G. (2013). Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut, 62(1), 159-176.

Staudacher, H. M., Lomer, M. C. E., Anderson, J. L., Barrett, J. S., Muir, J. G., Irving, P. M., & Whelan, K. (2017). Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. Journal of Nutrition, 147(8), 1446-1452.

Tana, C., Umesaki, Y., Imaoka, A., Handa, T., Kanazawa, M., & Fukudo, S. (2010). Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterology & Motility, 22(5), 512-519.

Wilson, B., Rossi, M., Dimidi, E., & Whelan, K. (2017). Prebiotics in irritable bowel syndrome and other functional bowel disorders in adults: a systematic review and meta-analysis of randomized controlled trials. American Journal of Clinical Nutrition, 107(6), 940-952.